InnaVirVax
Entity

  • InnaVirVax

    Created in 2008

  • Social networks

    467

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    4 Rue Pierre Fontaine, 91000 Évry-Courcouronnes, France

    Évry-Courcouronnes

    France

  • Employees

    Scale: 11-50

  • SIREN

    590208328

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    5 years, 6 months ago
Description
  • Value proposition

    InnaVirVax is a French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and cancer therapies.

    InnaVirVax is developing product candidates resulting from a beakthrough discovery, made at Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes (CD4) in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover, InnaVirVax has an AIDS prognostic test in its R&D portfolio. Lastly, InnaVirVax is developing an innovative cancer biotherapy.

    The discovery has identified that a dysregulation of the innate immune system is responsible for the loss of CD4 in HIV-infected patients. The understanding of this dysregulation (resulting in the presence at the surface of the CD4 of a NK cell ligand, making CD4 sensitive to NK-mediated cell lysis) has allowed InnaVirVax to design a therapeutic vaccine for HIV infection that has been successfully tested in non human primates and which has now recieved the authorization to run a first in man study. In addition InnaVirVax is developing an innovative cancer therapy.

    HIV therapy, cancer, HIV disease prognostic, and infectious diseases

  • Original language

    InnaVirVax is a French privately-owned biopharmaceutical company dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognostic of AIDS and HIV infection, other infectious diseases, and cancer therapies.

    InnaVirVax is developing product candidates resulting from a beakthrough discovery, made at Inserm, the French Medical research council, the AP-HP, the largest hospital in Europe, and University Pierre et Marie Curie in Paris. Based on a new paradigm (i.e. the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes (CD4) in HIV-infected patients), the products currently developed by InnaVirVax will allow the prevention and the treatment of AIDS in HIV-infected patients. Moreover, InnaVirVax has an AIDS prognostic test in its R&D portfolio. Lastly, InnaVirVax is developing an innovative cancer biotherapy.

    The discovery has identified that a dysregulation of the innate immune system is responsible for the loss of CD4 in HIV-infected patients. The understanding of this dysregulation (resulting in the presence at the surface of the CD4 of a NK cell ligand, making CD4 sensitive to NK-mediated cell lysis) has allowed InnaVirVax to design a therapeutic vaccine for HIV infection that has been successfully tested in non human primates and which has now recieved the authorization to run a first in man study. In addition InnaVirVax is developing an innovative cancer therapy.

Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics